• August 2022 - Jama Dermatology
    DOI:10.1001/jamadermatol.2022.2044

Although isotretinoin can rarely be associated with laboratory abnormalities such as hypertriglyceridemia, the optimal approach to laboratory monitoring is uncertain and there is wide variability in clinical practice.

The 22 participants from 5 continents reached consensus for the following: check alanine aminotransferase (ALT) within one month before initiation (89.5%) and at maximum dose (89.5%) but not monthly (76.2%) or after completion of treatment (73.7%); check triglycerides within one month before initiation (89.5%) and at maximum dose (78.9%) but not monthly (84.2%) or after completion of treatment (73.7%); do not check complete blood count and baseline metabolic panel parameters at any time during isotretinoin treatment (all >70%); do not check gamma-glutamyl transferase (78.9%), bilirubin (81.0%), albumin (72.7%), total protein (72.7%), lipoprotein (73.7%), and C-reactive protein (77.3%).